Cedelizumab
Cedelizumab
Cedelizumab (pronounced: seh-deh-lee-zoo-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a type of biopharmaceutical that is developed through recombinant DNA technology.
Etymology
The name "Cedelizumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-lizu-" is used for immunomodulating antibodies.
Mechanism of Action
Cedelizumab works by binding to a specific target on the surface of certain cells in the immune system. This binding action can block the activity of these cells, reducing the immune response that contributes to the development of autoimmune diseases.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Recombinant DNA: DNA that has been formed artificially by combining constituents from different organisms.
External links
- Medical encyclopedia article on Cedelizumab
- Wikipedia's article - Cedelizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski